Evidence map›Paper›PMID 29190678›Full record

ArticlePloS one2017

Type I interferon signaling restrains IL-10R+ colonic macrophages and dendritic cells and leads to more severe Salmonella colitis.

Kailyn L Stefan, Avner Fink, Neeraj K Surana, Dennis L Kasper, Suryasarathi Dasgupta

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Type I interferon remodels lysosome function and modifies intestinal epithelial defense.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  5. Autocrine-paracrine prostaglandin ENature immunology · 2018
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kailyn L StefanDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.
Avner FinkDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.
Neeraj K SuranaDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.
Dennis L KasperDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.
Suryasarathi DasguptaDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID http://orcid.org/0000-0003-1421-9559
Harvard University · USBoston Children's Hospital · US

Funding

INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
Deconstructing how the microbiota influences the mucosal innate immune systemK08AI108690 · NIAID · DUKE UNIVERSITY · PI SURANA, NEERAJ K · 2014 to 2018
$926k
NIAID NIH HHS K08 AI108690NIAID NIH HHS T32 AI007061
6 · The paper itself

Abstract

Type I interferons (IFNα, IFNβ) are key regulators of innate and adaptive immunity, modulating the severity of both viral and bacterial infections. While type I IFN signaling leads to improved outcomes in viral infections, its role in bacterial infections is more contextual and depends on the specific pathogen and route of infection. Given the limited evidence on whether type I IFN signaling affects enteric bacterial pathogens, we investigated the role of this signaling pathway in Salmonella enterica serovar Typhimurium (S. typhimurium)-induced colitis. Comparing mice deficient in IFNAR1- the common receptor for IFNα and IFNβ- with wild-type mice, we found that type I IFN signaling leads to more rapid death, more severe colonic inflammation, higher serum levels of pro-inflammatory cytokines, and greater bacterial dissemination. Specific ablation of plasmacytoid dendritic cells (pDCs), which are prominent producers of type I IFNs in antiviral responses, did not alter survival after infection. This result established that pDCs do not play a major role in the pathogenesis of S. typhimurium colitis. Flow cytometric analysis of macrophages and conventional dendritic cells (cDCs) during active colitis demonstrated an increase in CD11c- macrophages and CD103+ cDCs in the colon of Ifnar1-/- animals. Interestingly, cells expressing the anti-inflammatory cytokine receptor IL-10R are more abundant within these subsets in Ifnar1-/- than in wild-type mice. Moreover, blockade of IL-10R in Ifnar1-/- mice increased their susceptibility to S. typhimurium colitis, suggesting that altered numbers of these immunoregulatory cells may underlie the difference in disease severity. This cross-talk between type I IFN and IL-10R signaling pathways may represent a key host cellular mechanism to investigate further in order to unravel the balance between pathogenic inflammation and homeostasis of the colon. Taken together, our data clearly demonstrate that type I IFN signaling is pathogenic in S. typhimurium colitis.

Indexed as

Signal TransductionAnimalsColitisCytokinesDendritic CellsInterferon Type IIntestinal MucosaMacrophagesMiceMice, Inbred C57BLMice, TransgenicReceptors, Interleukin-10Salmonella InfectionsSalmonella typhimuriumSeverity of Illness IndexCytokinesInterferon Type IReceptors, Interleukin-10

Identifiers

PMID29190678
PMCPMC5708670
OpenAlexW2771964048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.